Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

Cancer(2022)10.1002/cncr.34445Source: DataRank Database

Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting is a research paper published in Cancer (2022). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 1.29)OA: hybridTopics (31)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Judith G. Villablanca ORCID,Barbara Hero ORCID,Brian H. Kushner ORCID,Keith Wheatley ORCID,Klaus Beiske ORCID

Live enrichment

PubMed:36101004 PMC:PMC9614386 OpenAlex:https://openalex.org/W4295759488

Cancer Research UK

Grant: 25354

Intramural NIH HHS

Grant: Z99 CA999999

NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research

Alex's Lemonade Stand Foundation for Childhood Cancer

Institute of Cancer Research

National Institute for Health Research (NIHR)

FWCI

1.29

Citation Percentile

0.8%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.34445

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.34445

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34445

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/cncr.34445

publisherhttps://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34445

Fields of Study

Neuroblastoma Research and TreatmentsCancer, Hypoxia, and MetabolismCancer therapeutics and mechanisms3-IodobenzylguanidineChildHumansNational Cancer Institute (U.S.)NeuroblastomaTreatment OutcomeUnited States

MeSH Terms

ChildHumansNeuroblastomaUnited StatesTreatment Outcome3-IodobenzylguanidineConsensusNational Cancer Institute (U.S.)

Keywords

MedicineClinical trialProgressive diseaseDiseaseNeuroblastomaRefractory (planetary science)Internal medicineOncologyGanglioneuroblastomaIntensive care medicineGanglioneuromaEarly phaseConsensus Criteria

Sustainable Development Goals

SDG 0: Partnerships for the goals